Azurity Pharmaceuticals has acquired Sebela Pharmaceuticals' bowel prep franchise, enhancing its gastrointestinal portfolio and commitment to patient care.

Information on the Target

Azurity Pharmaceuticals has successfully acquired the bowel prep franchise from Sebela Pharmaceuticals, which includes two prominent bowel preparation therapies designed for colonoscopies. This acquisition is pivotal in bolstering Azurity's existing portfolio in the gastrointestinal (GI) sector.

Ronald Scarboro, CEO of Azurity Pharmaceuticals, expressed enthusiasm about the acquisition, stating that the integration of Sebela's GI team and product lineup aligns with Azurity's long-term growth objectives and enhances its commitment to patient care in gastroenterology.

Industry Overview

In the United States, the gastroenterology market has been steadily growing, driven by an increasing prevalence of gastrointestinal diseases and a rising demand for advanced th